Proteomic approaches in cancer risk and response assessment

Emanuel F Petricoin1, Lance A Liotta

  • 1FDA-NCI, Clinical Proteomics Program, Building 29A, Room 2D12, 8800 Rockville Pike, Bethesda, MD 20892, USA. petricoin@cber.fda.gov